- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03421509
Cutaneous Silent Period and Spasticity
The Association Between Cutaneous Silent Period Parameters and Spasticity in Patients With Stroke
Study Overview
Detailed Description
The cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows a noxious cutaneous nerve stimulation. Studies in patients with central disorders of motor control such as dystonia and Parkinson's disease have shown CSP abnormalities indicating that supraspinal pathways influence this inhibitory spinal reflex. Spasticity is a serious problem that creates great difficulty for both patients and clinicians. The Support Programme for Assembly of a database for Spasticity Measurement (SPASM) group defined the spasticity as "disordered sensory-motor control, resulting from an upper motor neuron lesion, presenting as intermittent or sustained involuntary activation of muscles". Spasticity occurs in different types depending on the duration of the lesion present in the central nervous system (acute or slowly emerging), the size of the lesion and the location of the lesion such as cerebral cortex, brain stem or spinal cord. There are three major approaches, clinical, neurophysiological and biomechanical, for assessing spasticity. Stimulating the cutaneous nerve of the index finger at low-intensity, researchers have evoked an inhibition of the electromyographic (EMG) activity with a long latency and a short duration, namely the I2 inhibitory response of the cutaneo-muscular reflexes in the hand. ıt was suggested that the I2 inhibitory response, whose latency and duration overlap the CSP, was mediated by low-threshold, large-diameter fibers. Hence, because high-intensity electrical stimuli used to evoke the CSP activate large-diameter as well as small-diameter fibers, both fiber types may contribute in generating the CSP .
The central neural substrates producing the alpha-motor neuron inhibition after high-intensity stimulation differ from those after low-intensity stimulation. Low-intensity non-painful stimulation elicits a typical polysynaptic pattern of exteroceptive reflexes, whereas high-intensity electrical stimulation elicits an oligosynaptic pattern. Several studies investigated whether the CSP after high intensity finger stimulation arises from interruption of the excitatory drive to motor neurons (pre-synaptic inhibition) or inhibition of motor neurons themselves (post-synaptic inhibition). Studies using H-reflexes, F waves, and motor evoked potentials to assess motor neuron excitability showed that during the CSP motor neurons mainly receive post-synaptic inhibition transmitted through spinal inhibitory interneurons. Studies in patients with central disorders of motor control such as dystonia and Parkinson's disease have shown CSP abnormalities indicating that supraspinal pathways influence this inhibitory spinal reflex.
It was investigated whether the CSP parameters, F parameters are different between patients with stroke and amyotrophic lateral sclerosis (ALS) and healthy controls.
They found that CSP latency was higher in patients with stroke and ALS than healthy subjects. There was no difference in KSP duration and F-latency compared to healthy subjects. Contrary to these results, in another study did not show a relationship between spasticity and CSP parameters in twelve patients with stroke. The results of the existing studies on the relationship between spasticity and CSP parameters are conflicting. The influence of the descending suprasegmental pathways on the origin of the CSP is yet to be elucidated. Therefore; there is a need for a properly designed study investigating this relationship in a homogeneous sample. Given these results, we aimed to investigate the association between CSP parameters (duration and latency) and spasticity in patients with stroke. modified Ashworth scale, Modified Tardieu scale, Brunnstrom motor stage ve Fugl Meyer upper extremity score, Barthel index will be measured. Patients with stroke will underwent electromyographic assessments of F-wave latency, F-M ratio, CSP latency and duration, upper extremity nerve conduction studies. Association between clinical assessments and electrophysiological assessments will be investigated.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey, 34899
- Recruiting
- Marmara University School of Medicine Department of Physical Medicine and Rehabilitation
-
Contact:
- Giray Esra, MD
- Phone Number: +905558134394
- Email: girayesra@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- First ever time stroke
- Time since stroke >1 month
- Being able to understand the instructions (mini mental test score>24)
Exclusion Criteria:
- Diseases which might affect CSP parameters (Parkinsonism, restless leg syndrome, carpal tunel syndrome etc.)
- Autonomic nervous system disease
- Antispasticity medication use
- Hemiplegic shoulder pain
- Botulinum toxin injection within 6 months
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cutaneous silent period latency (ms)
Time Frame: Day 1
|
the brief interruption in voluntary contraction that follows strong electrical stimulation (painful) of a cutaneous nerve.
time between the stimulation and beginning of the silent period.
|
Day 1
|
|
Cutaneous silent period duration (ms)
Time Frame: Day 1
|
the brief interruption in voluntary contraction that follows strong electrical stimulation (painful) of a cutaneous nerve.
CSP duration is defined as the time between the beginning and endpoint of the silent period
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Ashworth Scale wrist
Time Frame: Day 1
|
Scores range from 0-4, with 5 choices 0 (0) - No increase in muscle tone 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement) 2 (3) - More marked increase in musce tone through most of the ROM, but affect part(s) easily moved 3 (4) - Considerable increase in muscle tone passive, movement difficult 4 (5) - Affected part(s) rigid in flexion or extension |
Day 1
|
|
Modified Ashworth Scale finger flexors
Time Frame: Day 1
|
Scores range from 0-4, with 5 choices 0 (0) - No increase in muscle tone 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement) 2 (3) - More marked increase in musce tone through most of the ROM, but affect part(s) easily moved 3 (4) - Considerable increase in muscle tone passive, movement difficult 4 (5) - Affected part(s) rigid in flexion or extension |
Day 1
|
|
Modified Tardieu Scale R1 wrist
Time Frame: Day 1
|
The angle of full ROM (R2) is taken at a very slow speed (V1).
The angle of muscle reaction (R1) is defined as the angle in which a catch or clonus is found during a quick stretch (V3).
R1 is then subtracted from R2 and this represents the dynamic tone component of the muscle
|
Day 1
|
|
Modified Tardieu Scale R1 finger flexors
Time Frame: Day 1
|
The angle of full ROM (R2) is taken at a very slow speed (V1).
The angle of muscle reaction (R1) is defined as the angle in which a catch or clonus is found during a quick stretch (V3).
R1 is then subtracted from R2 and this represents the dynamic tone component of the muscle
|
Day 1
|
|
Modified Tardieu Scale R2 wrist
Time Frame: Day 1
|
The angle of full ROM (R2) is taken at a very slow speed (V1).
The angle of muscle reaction (R1) is defined as the angle in which a catch or clonus is found during a quick stretch (V3).
R1 is then subtracted from R2 and this represents the dynamic tone component of the muscle
|
Day 1
|
|
Modified Tardieu Scale R2 finger flexors
Time Frame: Day 1
|
The angle of full ROM (R2) is taken at a very slow speed (V1).
The angle of muscle reaction (R1) is defined as the angle in which a catch or clonus is found during a quick stretch (V3).
R1 is then subtracted from R2 and this represents the dynamic tone component of the muscle
|
Day 1
|
|
Modified Tardieu Scale R2-R1 wrist
Time Frame: Day 1
|
The angle of full ROM (R2) is taken at a very slow speed (V1).
The angle of muscle reaction (R1) is defined as the angle in which a catch or clonus is found during a quick stretch (V3).
R1 is then subtracted from R2 and this represents the dynamic tone component of the muscle
|
Day 1
|
|
Modified Tardieu Scale R2-R1 finger flexors
Time Frame: Day 1
|
The angle of full ROM (R2) is taken at a very slow speed (V1).
The angle of muscle reaction (R1) is defined as the angle in which a catch or clonus is found during a quick stretch (V3).
R1 is then subtracted from R2 and this represents the dynamic tone component of the muscle
|
Day 1
|
|
Brunnstrom stage arm
Time Frame: Day 1
|
Motor recovery stage after stroke The Seven Brunnstrom Stages of Motor Recovery (see table below for more details)
|
Day 1
|
|
Brunnstrom stage hand
Time Frame: Day 1
|
Motor recovery stage after stroke The Seven Brunnstrom Stages of Motor Recovery (see table below for more details)
|
Day 1
|
|
Fugl Meyer upper extremity score
Time Frame: Day 1
|
Items are scored on a 3-point ordinal scale 0 = cannot perform
|
Day 1
|
|
Barthel index
Time Frame: Day 1
|
ordinal scale used to measure performance in activities of daily living (ADL) Minimum-maximum score: 0-100
|
Day 1
|
|
F wave latency
Time Frame: Day 1
|
the time from the onset of the stimulation artifact to the first deflection of the waveform from baseline <32 ms when obtained from median/ulnar nerves
|
Day 1
|
|
F/M ratio
Time Frame: Day 1
|
The F/M ratio compares proximal and distal segments and is useful in evaluating conduction time from stimulation site to spinal cord
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gulseren Derya AKYÜZ, Prof, Marmara University
Publications and helpful links
General Publications
- Floeter MK. Cutaneous silent periods. Muscle Nerve. 2003 Oct;28(4):391-401. doi: 10.1002/mus.10447.
- Gilio F, Bettolo CM, Conte A, Iacovelli E, Frasca V, Serrao M, Giacomelli E, Gabriele M, Prencipe M, Inghilleri M. Influence of the corticospinal tract on the cutaneous silent period: a study in patients with pyramidal syndrome. Neurosci Lett. 2008 Mar 12;433(2):109-13. doi: 10.1016/j.neulet.2007.12.055. Epub 2008 Jan 10.
- Kwang-Ik Jung WK. The Relationship between Cutaneous Silent Period and Spasticity in Patients with Stroke. Jouranl of Korean Association of EMG Electrodiagnostic Medicine, 10( 1), 1- 5. 2008.
- Naghdi S, Ansari NN, Abolhasani H, Mansouri K, Ghotbi N, Hasson S. Electrophysiological evaluation of the Modified Tardieu Scale (MTS) in assessing poststroke wrist flexor spasticity. NeuroRehabilitation. 2014;34(1):177-84. doi: 10.3233/NRE-131016.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09.2017.679
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
Clinical Trials on cutaneous silent period
-
Cairo UniversityRecruiting
-
Marmara UniversityCompletedSmall Fiber Neuropathy | Primary Sjögren SyndromeTurkey
-
MindWave Medical IncCompletedNursing Workload | Burnout, Healthcare Workers | Alarm Fatigue | Delirium in the Intensive Care Unit | Alarms | Noise in the ICU | Alarm Fatigue in Intensive Care Unit NursesIndia
-
DePuy InternationalTerminatedSecondary Arthritis | Primary ArthritisDenmark, Germany, Italy, Spain, United Kingdom
-
University Medical Centre LjubljanaUniversity of LjubljanaRecruitingAcute Myocardial Infarction | Silent Myocardial IschemiaSlovenia
-
Maltepe UniversityEnrolling by invitationDomestic Violence | Violence Against Women (VAW) | Awareness Training | EMPATHY İN NURSİNGTurkey (Türkiye)
-
Saglik Bilimleri Universitesi Gazi Yasargil Training...CompletedPediatric SedationTurkey (Türkiye)
-
DePuy InternationalJohnson and Johnson MedicalCompletedOsteoarthritisAustralia, Germany
-
DePuy InternationalJohnson & JohnsonTerminatedOsteoarthritisUnited Kingdom, Australia, France, Germany, Italy
-
Daewoong Pharmaceutical Co. LTD.Not yet recruiting